Effects of repeated-dose isradipine on the abuse liability of cocaine.

Roache, John D.; Johnson, Bankole A.; Ait-Daoud, Nassima; Mauldin, James B.; Thornton, Joe E.; Wells, Lynda T.; Murff, William

doi:10.1037/1064-1297.13.4.319

Cited by 22 publications

(29 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some results have been considered particularly encouraging; for example, an LCCBmediated increased the ability to refuse further doses of methamphetamine (Johnson et al, 1999). However, LCCBs have also been reported to enhance some subjective effects of abused drugs (Vaupel et al, 1993;Roache et al, 2005). The explanation for these mixed results is unclear, since divergent results have been seen even in studies examining drug-dependent individuals with a double-blind design.…”

Section: L-type Calcium Channels: Human Studiesmentioning

confidence: 99%

Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation

Addolorato

Leggio

Hopf

et al. 2011

Neuropsychopharmacol

View full text Add to dashboard Cite

Drug addiction represents a major social problem where addicts and alcoholics continue to seek and take drugs despite adverse social, personal, emotional, and legal consequences. A number of pharmacological compounds have been tested in human addicts with the goal of reducing the level or frequency of intake, but these pharmacotherapies have often been of only moderate efficacy or act in a sub-population of humans. Thus, there is a tremendous need for new therapeutic interventions to treat addiction. Here, we review recent interesting studies focusing on gamma-aminobutyric acid receptors, voltage-gated ion channels, and transcranial magnetic stimulation. Some of these treatments show considerable promise to reduce addictive behaviors, or the early clinical studies or pre-clinical rationale suggest that a promising avenue could be developed. Thus, it is likely that within a decade or so, we could have important new and effective treatments to achieve the goal of reducing the burden of human addiction and alcoholism.

show abstract

Section: L-type Calcium Channels: Human Studiesmentioning

confidence: 99%

Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation

Addolorato

Leggio

Hopf

et al. 2011

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…As summarized in Table III, conflicting results have been reported in preliminary clinical studies examining stimulants' abuse liability in humans [Muntaner et al, 1991;Rosse et al, 1994;Fabian and Silverstone, 1997;Johnson et al, 1999Johnson et al, , 2004Johnson et al, , 2005bMalcolm et al, 1999;Gottschalk and Kosten, 2002;Sofuoglu et al, 2003;Roache et al, 2005]. Roache et al [2005] suggested that isradipine could even increase subjective effects and reinforcement caused by cocaine use.…”

Section: Psychostimulantsmentioning

confidence: 99%

“…Roache et al [2005] suggested that isradipine could even increase subjective effects and reinforcement caused by cocaine use. On the contrary, some positive findings have been published for isradipine in methamphetamine addicts [Johnson et al, 2005a].…”

Section: Psychostimulantsmentioning

confidence: 99%

“…Isradipine attenuated blood pressure (BP) changes Sofuoglu et al [2003] SR-isradipine (15, 30 mg) No benefits on cocaine effects, abuse liability or craving Johnson et al [2004] Isradipine 30 mg 8 12 cocaine-dependent and 19 amphetamine-dependent subjects DB, Rz PC, CO; two 8-day study periods separated by at least 1 wk; EKG, heart rate (HR) and blood pressure (BP) Isradipine reduced stimulant-associated increases in BP but produced elevation of HR Johnson et al [2005a,b] SR-Isradipine 30 mg 10 12 cocaine-dependent subjects DB, PC, CO Isradipine enhanced rather than reduced subjective effects of cocaine Roache et al [2005] CBF, cerebral blood flow; CO, cross-over; DB, double-blind; OL, open-label; P, placebo; PC, placebo-controlled; Pts, patients; RCT, randomized controlled trial; Rz, randomized; mo, month; wk, week.…”

Section: Neurodegenerative Disorders Learning and Memorymentioning

confidence: 99%

See 1 more Smart Citation

L‐type calcium channels and psychiatric disorders: A brief review

Casamassima

Hay

Benedetti

et al. 2010

American J of Med Genetics Pt B

116

View full text Add to dashboard Cite

Emerging evidence from genome-wide association studies (GWAS) support the association of polymorphisms in the alpha 1C subunit of the L-type voltage-gated calcium channel gene (CACNA1C) with bipolar disorder. These studies extend a rich prior literature implicating dysfunction of L-type calcium channels (LTCCs) in the pathophysiology of neuropsychiatric disorders. Moreover, calcium channel blockers reduce Ca(2+) flux by binding to the α1 subunit of the LTCC and are used extensively for treating hypertension, preventing angina, cardiac arrhythmias and stroke. Calcium channel blockers have also been studied clinically in psychiatric conditions such as mood disorders and substance abuse/dependence, yielding conflicting results. In this review, we begin with a summary of LTCC pharmacology. For each category of disorder, this article then provides a review of animal and human data. In particular, we extensively focus on animal models of depression and clinical trials in mood disorders and substance abuse/dependence. Through examining rationale and study design of published clinical trials, we provide some of the possible reasons why we still do not have definitive evidence of efficacy of calcium-channel antagonists for mood disorders. Refinement of genetic results and target phenotypes, enrollment of adequate sample sizes in clinical trials and progress in physiologic and pharmacologic studies to synthesize tissue and isoform specific calcium channel antagonists, are all future challenges of research in this promising field. © 2010 Wiley-Liss, Inc.

show abstract

“…We used it in previous studies demonstrating reliable dose-related cocaine effects amenable to alteration by putative treatment agents (Johnson et al . 2004, 2007a; Roache et al . 2005).…”

Section: Methodsmentioning

confidence: 99%

Topiramate's effects on cocaine‐induced subjective mood, craving and preference for money over drug taking

et al. 2012

Self Cite

View full text Add to dashboard Cite

Topiramate, presumably through antagonism of excitatory glutaminergic pathways and facilitation of inhibitory gamma-aminobutyric acid neurons in the cortico-mesolimbic system, might reduce cocaine’s abuse liability. We tested whether topiramate (100 mg twice daily) would reduce the euphoria, subjective mood, craving, and preference for cocaine over money induced by low and high doses (0.325 and 0.650 mg/kg i.v., respectively) of experimentally administered cocaine in 24 male and female, cocaine-dependent, non-treatment-seeking research volunteers in a university inpatient laboratory. We utilized a randomized, double-blind, placebo-controlled, within-subject, Latin-square crossover design in which 3 experimental challenge doses of low-dose cocaine, high-dose cocaine, and placebo were administered in counterbalanced order after 5 days of topiramate or matching placebo pretreatments separated by a 1-week washout period (2006–2009). After placebo pretreatments, cocaine produced dose-related increases in euphoria, stimulant effects, craving for more cocaine, and monetary value of cocaine in a behavioral preference test of cocaine vs. money choice. Topiramate pretreatment reduced the cocaine-related craving and monetary value of high-dose cocaine while increasing the monetary value, euphoria, and stimulant effects of low-dose cocaine. Validated and standardized human experimental methods evaluating the potential for topiramate to alter cocaine’s abuse liability suggest that topiramate may reduce the reinforcing effects and craving induced by higher cocaine doses. Low-dose cocaine might appear to have some enhancement of its stimulant properties in the presence of topiramate’s prominent sedative effects.

show abstract

Effects of repeated-dose isradipine on the abuse liability of cocaine.

Cited by 22 publications

References 26 publications

Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation

Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation

L‐type calcium channels and psychiatric disorders: A brief review

Topiramate's effects on cocaine‐induced subjective mood, craving and preference for money over drug taking

Contact Info

Product

Resources

About